Renovaro Inc. (NASDAQ:RENB) Short Interest Update

by · The Markets Daily

Renovaro Inc. (NASDAQ:RENB – Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 3,870,000 shares, a growth of 27.7% from the November 30th total of 3,030,000 shares. Based on an average daily trading volume, of 869,400 shares, the short-interest ratio is presently 4.5 days. Currently, 5.0% of the company’s shares are sold short.

Hedge Funds Weigh In On Renovaro

Several large investors have recently bought and sold shares of the business. Barclays PLC raised its position in shares of Renovaro by 315.7% during the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after acquiring an additional 52,804 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Renovaro by 347.6% during the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock worth $45,000 after purchasing an additional 72,230 shares during the period. Rhumbline Advisers bought a new stake in Renovaro in the second quarter valued at about $79,000. Bank of New York Mellon Corp acquired a new position in Renovaro in the second quarter valued at about $220,000. Finally, State Street Corp boosted its stake in Renovaro by 3.8% during the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after acquiring an additional 48,114 shares during the last quarter. 71.41% of the stock is currently owned by institutional investors and hedge funds.

Renovaro Price Performance

Shares of NASDAQ RENB traded down $0.04 during midday trading on Tuesday, hitting $0.84. The stock had a trading volume of 366,774 shares, compared to its average volume of 628,313. Renovaro has a fifty-two week low of $0.40 and a fifty-two week high of $5.25. The firm has a market cap of $132.61 million, a P/E ratio of -0.87 and a beta of 0.65. The company’s 50-day simple moving average is $0.91 and its 200 day simple moving average is $0.91.

Renovaro (NASDAQ:RENB – Get Free Report) last announced its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) earnings per share for the quarter.

Renovaro Company Profile

(Get Free Report)

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.

Further Reading